Beckman Coulter Announces Test to Help Assess Cardiac Risk and Other Diseases.
FULLERTON, Calif.--(BW HealthWire)--March 6, 2002
Beckman Coulter, Inc. (NYSE:BEC) announced today it has released a new high-sensitivity laboratory test to help physicians determine a patient's risk of coronary artery disease.
The test -- called CRPH -- accurately measures levels of C-reactive protein (CRP), a protein produced in the liver and released into the bloodstream as a result of infection or injury, such as tissue damage or inflammation caused by coronary artery disease.
"CRPH can be performed as part of a routine, physical exam to help physicians identify individuals at increased risk of coronary artery disease," said Wing Pang, vice president-director of Beckman Coulter's clinical chemistry development center. "Studies show that more traditional cardiac screening methods identify only 50 percent of individuals with a predisposition to future coronary events. But performing high-sensitivity CRP testing in conjunction with these other screening methods -- such as tests that measure cholesterol, body weight and blood pressure -- can dramatically improve a physician's ability to assess risk of cardiovascular disease."
The new test also can aid physicians in the evaluation of stress, trauma, infection, inflammation, surgery and associated diseases.
The CRPH test is available on the company's IMMAGE(R) immunochemistry system and SYNCHRON LX(R)20 PRO chemistry analyzer.
CRPH is Beckman Coulter's second test for cardiac evaluation released in the last 12 months. In June 2001, the company launched Access(R) AccuTnI(TM), a troponin I test that aids in the diagnosis and treatment of heart attacks and cardiac muscle damage. The 12-minute test, which is one of the fastest available, is used by hospitals in routine and emergency situations. Access AccuTnI is available on Beckman Coulter's Access immunoassay systems.
Beckman Coulter, Inc. is a global biomedical company headquartered in Fullerton, Calif. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62 percent of this amount generated by recurring revenue from supplies, chemistry kits and services. For more information, visit www.beckmancoulter.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 6, 2002|
|Previous Article:||Penn National Gaming to Participate in Lehman Brothers 2002 High Yield Conference.|
|Next Article:||Small Town Radio/Worldwide PetroMoly Debuts New Radio Network.|